297 related articles for article (PubMed ID: 16643716)
1. Anabolic agents: a new chapter in the management of osteoporosis.
Khan AW; Khan A
J Obstet Gynaecol Can; 2006 Feb; 28(2):136-41. PubMed ID: 16643716
[TBL] [Abstract][Full Text] [Related]
2. Anabolic skeletal therapy for osteoporosis.
Girotra M; Rubin MR; Bilezikian JP
Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):745-54. PubMed ID: 17117299
[TBL] [Abstract][Full Text] [Related]
3. Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?
Girotra M; Rubin MR; Bilezikian JP
Treat Endocrinol; 2006; 5(6):347-58. PubMed ID: 17107220
[TBL] [Abstract][Full Text] [Related]
4. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
5. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
6. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
[TBL] [Abstract][Full Text] [Related]
8. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
Reginster JY; Deroisy R; Jupsin I
Drugs Today (Barc); 2003 Feb; 39(2):89-101. PubMed ID: 12698204
[TBL] [Abstract][Full Text] [Related]
9. Combination anabolic and antiresorptive therapy for osteoporosis.
Cusano NE; Bilezikian JP
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434
[TBL] [Abstract][Full Text] [Related]
10. Strontium ranelate in osteoporosis.
Reginster JY
Curr Pharm Des; 2002; 8(21):1907-16. PubMed ID: 12171530
[TBL] [Abstract][Full Text] [Related]
11. Bone-forming agents in the management of osteoporosis.
Neuprez A; Reginster JY
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):869-83. PubMed ID: 19028361
[TBL] [Abstract][Full Text] [Related]
12. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone as an anabolic skeletal therapy.
Rubin MR; Bilezikian JP
Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
[TBL] [Abstract][Full Text] [Related]
14. Strontium ranelate--data on vertebral and nonvertebral fracture efficacy and safety: mechanism of action.
Kendler DL
Curr Osteoporos Rep; 2006 Mar; 4(1):34-9. PubMed ID: 16527006
[TBL] [Abstract][Full Text] [Related]
15. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
16. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
Ortolani S; Vai S
Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319
[TBL] [Abstract][Full Text] [Related]
17. The use of parathyroid hormone in the treatment of osteoporosis.
Girotra M; Rubin MR; Bilezikian JP
Rev Endocr Metab Disord; 2006 Jun; 7(1-2):113-21. PubMed ID: 17043762
[TBL] [Abstract][Full Text] [Related]
18. Anabolic agents for treating postmenopausal osteoporosis.
Meunier PJ
Joint Bone Spine; 2001 Dec; 68(6):576-81. PubMed ID: 11809001
[TBL] [Abstract][Full Text] [Related]
19. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.
Bilezikian JP; Rubin MR
Curr Osteoporos Rep; 2006 Mar; 4(1):5-13. PubMed ID: 16527002
[TBL] [Abstract][Full Text] [Related]
20. PTH (1-34): a novel anabolic drug for the treatment of osteoporosis.
Holick MF
South Med J; 2005 Nov; 98(11):1114-7. PubMed ID: 16353381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
